Accueil>>Signaling Pathways>> Apoptosis>> Other Apoptosis>>Isosilybin A

Isosilybin A

Catalog No.GC36343

L'isosilybine A, un flavonolignan isolé de la silymarine, a une activité anti-cancer de la prostate (PCA). L'isosilybine A inhibe la prolifération et induit l'arrêt de la phase G1 et l'apoptose dans les cellules cancéreuses, ce qui active la machinerie apoptotique dans les cellules PCA via le ciblage de l'axe Akt-NF-κB-récepteur aux androgènes (AR).

Products are for research use only. Not for human use. We do not sell to patients.

Isosilybin A Chemical Structure

Cas No.: 142796-21-2

Taille Prix Stock Qté
1mg
185,00 $US
En stock
5mg
324,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Isosilybin A, a flavonolignan isolated from silymarin, has anti-prostate cancer (PCA) activity. Isosilybin A inhibits proliferation and induces G1 phase arrest and apoptosis in cancer cells, which activates apoptotic machinery in PCA cells via targeting Akt-NF-κB-androgen receptor (AR) axis[1][2].

[1]. Deep G, et al. Isosilybin B and isosilybin A inhibit growth, induce G1 arrest and cause apoptosis in human prostatecancer LNCaP and 22Rv1 cells. Carcinogenesis. 2007 Jul;28(7):1533-42. [2]. Deep G, et al. Isosilybin A induces apoptosis in human prostate cancer cells via targeting Akt, NF-κB, and androgen receptor signaling. Mol Carcinog. 2010 Oct;49(10):902-12.

Avis

Review for Isosilybin A

Average Rating: 5 ★★★★★ (Based on Reviews and 39 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Isosilybin A

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.